More About Lilly’s mAb Therapy for COVID-19
- Posted by ISPE Boston
- On September 30, 2020
Eli Lilly has announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with SARS-CoV-2 neutralizing antibody LY-CoV555. The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555 for the treatment of symptomatic COVID-19 in the outpatient setting. LY-CoV555 is a potent, neutralizing […]
Read More